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Abstract
OBJECTIVE: To systematically review the efficacy
and safety of Traditional Chinese Medicine (TCM) in-
terventions, compared with control interventions
(placebo or conventional Western medical thera-
py), in the treatment of acquired immunodeficien-
cy syndrome (AIDS).
METHODS: Electronic databases including
PubMed, the Cochrane Library, China National
Knowledge Infrastructure (CNKI), and Wanfang Da-
ta were searched to identify relevant randomized
controlled trials (RCTs) published as of May 2012.
Studies were selected according to the specified in-
clusion and exclusion criteria and then subjected
to methodological quality assessment, data extrac-
tion, and meta-analysis according to the Cochrane
Handbook for Systematic Reviews of Interventions.
RESULTS: Twelve RCTs involving 881 patients with
AIDS were included. Methodological quality assess-
ment showed that two were high-quality, two were
moderate-quality, and eight were low-quality. Me-
ta-analysis showed that TCM interventions were as-
sociated with significantly reduced plasma viral
load compared with placebo [odds ratio OR=2.46,
95% confidence interval CI (1.02, 5.94); P=0.04].
However, the reductions in plasma viral load signifi-
cantly favored conventional Western medical thera-
py alone over integrated traditional Chinese and
Western medical therapy [OR=0.16, 95% CI (0.05,
0.55); P=0.004]. Patients receiving TCM interven-
tions had significantly higher CD4+ T lymphocyte
counts compared with those on placebo [OR=2.54,
95% CI (1.40, 4.60); P=0.002]. In addition, TCM inter-
ventions were significantly more likely to have im-
proved clinical symptoms [OR=2.82, 95% CI (1.85,
4.31); P<0.00001]. TCM interventions conferred a
similar risk of adverse events (AEs) compared with
control interventions [OR=1.87, 95%CI (0.58, 6.01);
P=0.29].
CONCLUSION: Current evidence suggests that
TCM interventions are significantly more effective
than placebo in reducing plasma viral load and in-
creasing CD4+ T lymphocyte count in patients with
AIDS. When compared with conventional Western
medical therapy, TCM interventions were signifi-
cantly less effective in reducing plasma viral load,
although they were associated with a higher per-
centage of patients with improved symptoms. Pa-
tients receiving TCM interventions did not seem to
be at an increased risk of AEs.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is a
highly transmissible disease caused by human immuno-
deficiency virus (HIV). There are approximately 33.3
million people living with HIV infection worldwide.
Despite an overall decline, the rate of HIV infection
has increased by more than 25% in eastern Europe and
central Asia since 2001.1 HIV infection is most preva-
lent in sub-Saharan Africa where it accounts for 67%
of the global HIV-infected population.2 By 2010, the
number of chronic HIV-infected patients in mainland
China has increased to 370 393.1 AIDS is a life-threat-
ening disease that causes heavy economic burdens and
other significant indirect losses.3 There are no effective
vaccines for the prevention of AIDS, but various treat-
ments have been developed. Highly active anti-retrovi-
ral therapy (HAART) is the preferred choice for the
prevention and treatment of AIDS.4 HAART has been
found to be beneficial for patients with AIDS though
it has some limitations.5,6 Many asymptomatic HIV-in-
fected patients remain untreated because of current rec-
ommendations against the use of antiviral therapy for
such patients.
Traditional Chinese Medicine (TCM) can significantly
improve symptoms, increase and stabilize immune
function and quality of life, and reduce toxicity of anti-
viral drugs in patients with AIDS.7-16 The promising ef-
ficacy of TCM in the treatment of AIDS has generated
great interest worldwide. However, there is a scarcity of
systematic reviews on the efficacy and safety of TCM
interventions in AIDS. This article presents a Co-
chrane systematic review of relevant published random-
ized controlled trials (RCTs) to provide evidence-based
support for the use of TCM in the clinical treatment of
AIDS.
DATA ANDMETHODS
Inclusion criteria
Type of study: full-text RCTs investigating the use of
oral TCM for the treatment of AIDS in China and oth-
er countries were included, regardless of use of blind-
ing, or the types and languages of publication.
Subjects: study population included patients with
AIDS or AIDS-related diseases, regardless of sex, age,
race, or ethnicity. A diagnosis of AIDS was made20 if a
test for HIV antibodies was positive and a CD4 + T
lymphocyte count was less than 200 cells/µL. Addition-
ally, AIDS was diagnosed if there was an epidemiologi-
cal history and a positive HIV antibody test with the
presence of any one of the following: (a) unexplained
irregular fever of 38℃ or higher lasting for more than
1 month; (b) diarrhea (more than three defecations per
day) for more than 1 month; (c) body mass loss of
more than 10% in the past 6 months; (d) recurrent
Candida infection; (e) recurrent herpes simplex or zos-
ter infection; (f ) pneumocystis carinii pneumonia; (g)
recurrent bacterial pneumonia; (h) active tuberculosis
or nontuberculous mycobacterial disease; (i) deep fun-
gal infection; (j) central nervous system lesions; (k) de-
mentia in young or middle-aged adults; (l) active cyto-
megalovirus infection; (m) toxoplasmic encephalitis;
(n) penicillium infection; (o) recurrent sepsis; or (p) mu-
cocutaneous or visceral Kaposi's sarcoma, lymphoma.
Interventions: patients in the experimental group oral-
ly received traditional Chinese medical treatment (Chi-
nese herbal compounds) alone or in combination with
conventional Western medical treatment. In the con-
trol group, patients were treated with conventional
Western medical intervention or placebo.
Outcome measures: the primary endpoint was reduc-
tion in plasma viral load (HIV-IRNA). The secondary
endpoints included increases in CD4 + T lymphocyte
count, the percentage of patients with improved clini-
cal symptoms, and adverse event (AE) rates. Assess-
ments of the virological measure (plasma viral load),
the immunological measure (CD4 + T lymphocyte
count), and the percentage of patients with improved
clinical symptoms were performed according to the cri-
teria described by the Joint United Nations Program
on HIV/AIDS (UNAIDS) and World Health Organi-
zation (WHO).1
Exclusion criteria
Studies were excluded if they were: (a) animal experi-
ments; (b) clinical trials from which no relevant data
could be extracted; (c) studies that were repeatedly pub-
lished; (d) patients with serious mental disorders or de-
mentia; (e) patients with serious systemic symptoms
that may significantly affect their ability to perform dai-
ly living activities, including syncope or coma, sei-
zure-like headache, and cachexia; (f ) women who were
pregnant or breastfeeding.
Search strategy
The search strategy was developed using the Cochrane
Handbook for Systematic Reviews of Interventions. To
identify relevant RCTs published in English or Chinese
as of May 2012, we performed a computerized search
in PubMed (1979-May 2012), The Cochrane Library
(1989-May 2012), China National Knowledge Infra-
structure (CNKI) (1979-May 2012), and Wanfang Da-
ta (1979-May 2012), and a manual search in Chinese
Journal of AIDS & STD, Chinese Journal of Clinical
Infectious Diseases, Chinese Archives of Traditional
Chinese Medicine, Chinese Journal of Integrated Tradi-
tional and Western Medicine, and Chinese Journal of
Basic Medicine in Traditional Chinese Medicine. Refer-
ences in the reports identified were also searched. In ad-
dition, we requested gray literature from relevant man-
ufacturers. For the English-language search in Pubmed
and The Cochrane Library, subject headings and
text-word searches were used, and the search terms in-
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cluded "Traditional Chinese Medicine", "TCM", "Ac-
quired Immunodeficiency Syndrome," "AIDS",
"HIV", "Randomized Controlled Trial", "RCT" and
their synonyms. For the Chinese-language search in
CNKI and Wanfang Data, we used the same search
strategy and search terms (in this case, Chinese equiva-
lents of the aforementioned English words were used).
Details on the search strategy are provided in the Ap-
pendix.
Literature screening and data extraction
The title and abstract of the identified reports were re-
viewed independently by two reviewers to exclude du-
plicated and non-RCT reports. Then, the full texts of
the remaining reports were examined for eligibility for
final inclusion according to the specified inclusion cri-
teria. Data extraction was conducted independently by
two reviewers using a predesigned extraction form. Da-
ta to be extracted included general information, inter-
ventions, and outcome measures. Discrepancies were
resolved by discussion or referral to a third reviewer. If
a study was potentially eligible for inclusion but lacked
sufficient data, the authors of the study were contacted
for additional information.
Assessment of methodological quality and evidence
quality
Methodological quality of the included RCTs was as-
sessed by the domains (randomization, allocation con-
cealment, blinding, complete outcome data, selective
outcome reporting, and other potential biases) de-
scribed by Higgins et al 19 in the Cochrane Handbook
for Systematic Reviews of Interventions (Version
5.1.4). Evidence quality was rated as high, moderate,
low, or very low using the GRADE 3.6 software.20
Statistical analysis
Meta-analysis was performed using the RevMan soft-
ware (version 5.1.4, RevMan software, London, Eng-
land) from The Cochrane Collaboration. First, we per-
formed clinical heterogeneity and methodological het-
erogeneity analyses for all the studies included. Statisti-
cal heterogeneity was evaluated by, the Chi-squared (χ2)
test and heterogeneity was considered present if P≤0.10.
Quantitative assessment of heterogeneity was per-
formed using I2 where I2>50% indicated high heteroge-
neity among study results. Study results were pooled
for analysis using a fixed effects model when there was
no statistical heterogeneity or using a random effects
model when statistical heterogeneity was detected. For
dichotomous variables, odds ratio (OR) and 95% confi-
dence interval (CI) was determined. For hypothesis
testing, the U test was used and the results were pre-
sented as Z and P values. The differences in the effica-
cy between interventions were considered statistically
significant if P≤0.05. The results of hypothesis testing
are presented in a forest plot.
RESULTS
Results of literature search and characteristics of the
included trials
Nine hundred and thirty one reports were identified
initially, including 178 from PubMed, seven from the
Cochrane Library, 270 from CNKI and 476 from Wan-
fang Data. By reading the title and abstract of the iden-
tified reports, we excluded 919 reports that were
non-RCTs, repeatedly published, or irrelevant to this
systematic review. The full texts of the remaining 18 ar-
ticles were examined and 6 of the 18 articles were ex-
cluded because of failure to meet the criteria for inclu-
sion in our systematic review. Therefore, 12 RCTs (2
published in English and 10 in Chinese) were finally
included.7-16 The 12 RCTs involved a total of 881 pa-
tients with AIDS, with 495 patients in the experimen-
tal group and 386 in the control group. Figure 1 is the
flowchart of study inclusion and exclusion. The charac-
teristics of the included study are shown in Table 1.
Figure 1 The flowchart of the literature search
Record excluded due to
-not meet intervention of the
inclusion criteria: n=2
-not meet type of research of the
inclusion criteria: n=1
-not extract data of dichotomous
variables: n=3
PubMed: n=178 Cochrane Library: n=7 CIKI: n=270 Wangfang: n=476
Total trials identified
by initial search in 4
database: n=937
Not a RCT
study and
unrelated study:
n=919
Check
full-text: n=18
Final
inclusion: n=12
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Results of methodological quality assessment
Assessment of methodological quality of the included
RCTs was performed using the risk of bias assessment
tool provided in the Cochrane Handbook19 (Table 2).
Of the 12 RCTs assessed, 2 were classified as high qual-
ity, 2 as moderate quality, and 8 as low quality.
Results of statistical analysis
Reductions in plasma viral load: Reductions in plasma
viral load were reported by three studies.9,15,17 Subgroup
analyses were performed by control interventions (i.e.,
placebo or conventional Western medical therapy).
For two studies9,15 using placebo as control, a fixed-ef-
fects model was used for pooled analysis owing to ab-
sence of statistical heterogeneity among the studies
(P=0.19, I2=42% ). Meta-analysis showed that TCM
therapy was significantly more effective in reducing
plasma viral load than placebo in the treatment of
AIDS [OR=2.46, 95% CI (1.02, 5.94); P=0.04]. In a
study17 comparing integrated traditional Chinese and
Western medical therapy with Western medical thera-
py alone in patients with AIDS, Western medical
Table 1 Characteristics of the included studies
Included
study
Liu CE
et al
20067
Jiang
QS
et al
20098
Li M et
al 20069
Yang
GH
et al
200810
Chen
M et al
200811
Jiang F
et al
200912
Tian M
et al
201113
Burack
JH
et al
199614
Wang J
et al
200615
Shi D
et al
200316
Zhao
HX
et al
200617
Liu HY
et al
200718
No. of
patients
(experimental
/control)
58/21
57/58
41/39
47/34
40/40
40/40
94/46
15/14
30/33
13/17
25/24
35/20
Intervention
Experimental
Modified
Pingwei powder
HAART+
Jingyuankang
capsules+
leucogen placebo
Fufangsanhuang-
san granules
Shenlingbaizhu
pills
Shenlingbaizhu
pills+
Zhenrenyangzang
decoction
Xiaomi granules
Jianpizhixie
formula
Chinese herbal
treatment
Zhongyan-4
Qiankunning
tablets
Zhongyaoxinxue
tablets+
didanosine+
nevirapine+
stavudine
Jingyuankang
capsules+
leucogen placebo
Control
Famotidine+
domperidon
e
HAART+
jingyuankan
g capsule
placebo+
leucogen
Placebo
Norfloxacin
capsules+
dioctahedral
smectite
Berberine
Nystatin
tablets
Loperamide
capsules
Placebo
Placebo
Placebo
Didanosine+
nevirapine+
stavudin
Leucogen+
Jingyuankan
g capsule
placebo
Male
60
39
80
29
43
46
80
28
32
30
26
25
Sex (n)
Female
19
76
0
52
37
34
50
1
31
0
24
30
Age (years),
median (range)
Experimental
37.7 (19-65)
42.4 (26-62)
NA
44.0 (28-60)
NA
44.6±7.0
NA
34.5±2.0
NA
25.8±5.1
40.2±8.7
44.5±10.6
Control
35.8
(22-62)
43.6
(29-62)
NA
43.0
(26-60)
NA
43.3±
7.5
NA
37.7±
7.4
NA
25.5±
4.8
40.0±
10.3
43.5±
9.8
Outcome
measure
f, g
c, g
g
f, g
g
f, g
c, g
b, d, f, g
a, b, c, e,
g
a, b, g
a, b, c, g
d, f, g
Duration
(weeks)
4
26
13
8
4
2
2
12
26
30
24
48
Notes: NA: not available; a: HIV-IRNA in plasma; b: CD4+ T lymphocyte count; c: adverse events; d: quality of life; e: HIV-IL2 in
plasma; f: symptom scores; g: percentage of patients with improved clinical symptoms.
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Included study
Liu CE et al 20067
Jiang QS et al 20098
Li M et al 20069
Yang GH et al 200810
Chen M et al 200811
Jiang F et al 200912
Tian M et al 201113
Burack JH et al 199614
Wang J et al 200615
Shi D et al 200316
Zhao HX et al 200617
Liu HY et al 200718
Randomization
Unclear
Unclear
Low risk
Unclear
Unclear
Unclear
Low risk
Low risk
Low risk
Low risk
Unclear
Low risk
Allocation
concealment
High risk
High risk
High risk
High risk
High risk
Low risk
Low risk
Low risk
High risk
Low risk
High risk
High risk
Blinding
High risk
Low risk
Unclear
High risk
High risk
High risk
High risk
Low risk
Low risk
Low risk
High risk
High risk
Incomplete
outcome
data
High risk
High risk
High risk
High risk
High risk
High risk
Low risk
Low risk
Low risk
Low risk
High risk
High risk
Selective
outcome
reporting
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Other
sources
of bias
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Table 2 Assessment of methodological quality of the included studies
Figure 2 Meta-analysis on reductions in plasma viral load by TCM therapy in patients with AIDS
TCM: Traditional Chinese Medicine; AIDS: immunodeficiency syndrome.
Figure 3 Meta-analysis on increases in CD4+ T lymphocyte count by TCM therapy in patients with AIDS
TCM: Traditional Chinese Medicine; AIDS: immunodeficiency syndrome.
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therapy alone was found to be associated with signifi-
cantly reduced plasma viral load [OR=0.16, 95% CI
(0.05, 0.55);P=0.004) (Figure 2).
Increases in CD4 + T lymphocyte count: Increases in
CD4 + T lymphocyte count were described in four
studies9,14-16 comparing TCM therapy with placebo in
AIDS. A fixed-effects model was used for pooled analy-
sis because there was no statistical heterogeneity among
the studies (P=0.69, I2=0% ). Meta-analysis showed
that TCM therapy was associated with a significantly
higher CD4+ T lymphocyte count compared with pla-
cebo in the treatment of AIDS (Figure 3).
Percentage of patients with improved clinical symp-
toms: Percentage of patients with improved clinical
symptoms was reported in seven studies7,8,10-13,18 compar-
ing TCM therapy with conventional Western medical
therapy in AIDS. A fixed-effects model was used for
pooled analysis because there was no statistical hetero-
geneity among the studies (P=0.27, I2=21% ). Me-
ta-analysis showed that patients with AIDS who re-
ceived TCM therapy were significantly more likely to
have improved clinical symptoms compared with those
on conventional Western medical therapy [OR=2.82,
95% CI (1.85, 4.31); P<0.000 01] (Figure 4).
Outcome
Reductions in
plasma viral load
(HIV-IRNA)
Increases in
CD4+ T
lymphocyte
count
Percentage of
patients with
improved clinical
symptoms
Rates of
drug-related
adverse events
Follow
-up
(weeks)
13-24
12-30
2-48
2-26
Item
Study
population
Moderate
Study
population
Moderate
Study
population
Moderate
Study
population
Moderate
Illustrative
Assumed risk
(oral Traditional
Chinese Medicine)
27 per 100
23 per 100
30 per 100
15 per 100
68 per 100
11 per 100
6 per 100
30 per 100
Comparative
Corresponding
risk (placebo or
western medical)
26 per 100
(15 to 40)
22 per 100
(13 to 35)
52 per 100
(38 to 66)
31 per 100
(20 to 45)
85 per 100
(79 to 90)
26 per 100
(19 to 35)
11 per 100
(4 to 29)
44 per 100
(20 to 72)
OR (95% CI)
0.95
(0.5, 1.81)
2.54
(1.40, 4.60)
2.82
(1.85, 4.31)
1.87
(0.58, 6.01)
No. of
participants
(studies)
194
(3 studies)
202
(4 studies)
630
(7 studies)
203
(2 studies)
Quality of
the evidence
(GRADE)
Moderate
Moderate
Moderate
Moderate
Table 3 Assessment of evidence quality by the GRADE criteria
Figure 4 Meta-analysis on the potential to improve clinical symptoms by TCM therapy in patients with AIDS
TCM: Traditional Chinese Medicine; AIDS: immunodeficiency syndrome.
Figure 5 Meta-analysis on the rates of AEs associated with TCM in patients with AIDS
TCM: Traditional Chinese Medicine; AEs: adverse events; AIDS: immunodeficiency syndrome.
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Rates of drug-related adverse events: Rates of drug-re-
lated AEs were reported by two trials.13,15 A fixed-effects
model was used for pooled analysis because no statisti-
cal heterogeneity was observed among the studies (P=
0.94, I2=0% ). Meta-analysis showed that TCM inter-
ventions were associated with similar rates of drug-relat-
ed AEs compared with control interventions in pa-
tients with AIDS [OR=1.87, 95%CI (0.58, 6.01), P=
0.29] (Figure 5).
Assessment of evidence quality
Table 3 shows the quality of the included RCTs' evi-
dence assessed by an approach developed by the
GRADE software (version 3.6, GRADE, London, Eng-
land).20 The GRADE system classifies the quality of evi-
dence into the following four grades: high quality: fur-
ther research is very unlikely to change our confidence
in the estimate of effect; moderate quality: further re-
search is likely to have an important impact on our
confidence in the estimate of effect and may change
the estimate; low quality: further research is very likely
to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate;
very low quality: we are very uncertain about the esti-
mate. The quality of evidence of the included RCTs
was generally graded as moderate.
DISCUSSION
In this study, we performed a search to identify clinical
trials investigating the efficacy and safety of TCM inter-
ventions for the treatment of AIDS in China and else-
where before May 2012. Meta-analysis found that TCM
interventions were significantly more effective than pla-
cebo in reducing plasma viral load and increasing CD4+
T lymphocyte count in patients with AIDS.When com-
pared with conventional Western medical therapy,
TCM interventions were significantly less effective in
reducing plasma viral load, although they were associat-
ed with a higher percentage of patients with improved
symptoms. Patients receiving TCM interventions did
not seem to be at an increased risk of AEs.
Integrity and practicality of the evidence
Although all the 12 studies included in this systematic
review claimed to be randomized controlled trials, only
six described specific randomization methods, while
the remaining six provided no such description. Four
RCTs reported and used appropriate allocation conceal-
ment whereas the other eight did not mention or speci-
fy allocation concealment and therefore were consid-
ered as having a moderate to high risk of selection bias.
Four RCTs employed blinding. In contrast, seven did
not use blinding or did not offer clear information
about blinding and one provided no such description.
These eight were therefore at a moderate to high risk
of measurement bias. Four RCTs reported the number
of patients who were lost to follow-up, dropout, or ex-
cluded from the studies, and used intention-to-treat
(ITT) analysis. The remaining eight RCTs provided no
such data, resulting in a moderate to high risk of data
completeness bias. None of the 12 RCTs selectively re-
ported outcomes and therefore there was a low risk of
reporting bias. The problems in the design of the in-
cluded trials may have limited the reliability of their
conclusions, thus reducing the strength of the conclu-
sion of this meta-analysis, warranting the need for
high-quality clinical studies with a low risk of bias.
Evidence quality
There are five factors that may contribute to a decrease
in evidence quality, including limitation in study de-
sign, inconsistency of results, indirectness of evidence,
imprecision of results, and publication bias. The stud-
ies included in our systematic review had consistent
and precise results, with no indirectness of evidence.
However, there were certain limitations in study design
and implementation and a risk of bias, resulting in pos-
sible exaggeration of the results. Therefore, the quality
of evidence was generally rated as moderate by the
GRADE criteria and the risk of bias was moderate.
Limitations
The RCTs included in our systematic review had a
moderate quality of evidence and a high risk of selec-
tion bias, implementation bias and measurement bias.
In addition, our systematic review did not include un-
published studies. Furthermore, the included RCTs dif-
fered in terms of treatment duration, disease severity,
time points at which outcome measures were assessed,
and methods used for outcome assessment. Finally,
there was a risk of bias in language distribution of the
included RCTs because our search was restricted to
RCTs published in English or Chinese. All these fac-
tors described above may have limited the strength of
the conclusion of our systematic review.
Efficacy and safety analyses
Our review showed that TCM interventions were asso-
ciated with a significantly higher percentage of patients
with improved clinical symptoms compared with con-
ventional Western therapy. This finding was consistent
with the conclusions by Yan et al.21,22 In addition, TCM
interventions were significantly more effective than pla-
cebo in reducing plasma viral load and increasing
CD4+ T lymphocyte count. TCM interventions were
not more effective than conventional Western therapy
in reducing plasma viral load. Regarding incidences of
AEs, TCM was comparable to conventional Western
therapy. These results suggest that TCM may be an ef-
fective and safe therapeutic option for the long-term
treatment of AIDS.
Significance for clinical practice and implications
for the future
In this report, we systematically reviewed the efficacy
and safety of TCM interventions versus conventional
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Western medical treatment or placebo in patients with
AIDS. We found that TCM interventions were signifi-
cantly more effective in increasing CD4 + T lympho-
cyte count and the percentage of patients with im-
proved clinical symptoms, although their ability to re-
duce viral plasma load was less remarkable. Currently,
the treatment of AIDS with TCM or TCM plus West-
ern medicine focuses more on improving symptoms,
quality of life and survival, and less on reducing plasma
viral load and increasing CD4+ T lymphocyte count.
Our finding suggests that patients with AIDS who
have significant clinical symptoms, significantly lower
immunity, or poor quality of life may benefit more
from TCM interventions and that TCM interventions
may be safely used for the long term treatment of
AIDS. The included 12 RCTs provided no direct evi-
dence linking TCM with reduced mortality in patients
with AIDS and associated disorders. The effectiveness
of TCM interventions in reducing long term mortality
in AIDS needs to be further investigated with larger
multi-center RCTs. Further clinical trials should focus
on the standardization of TCM-based pattern differen-
tiation and efficacy evaluation systems and should fol-
low patients long enough to collect more data on AEs
and losses to follow-up to reduce heterogeneity among
studies and increase methodological quality of the
studies.
In conclusion, future RCTs should use appropriate ran-
domization, allocation concealment and blinding, and
perform ITT analysis with complete data to improve
trial quality. Attention should be paid to clinical re-
ports with negative findings. It is recommended to con-
duct standardized RCTs in compliance with the IC-
MJE clinical trial registration policy23 and the Consoli-
dated Standards of Reporting Trials statement24 to pro-
vide stronger evidence for the use of TCM for AIDS in
clinical practice.
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